Charles Schwab
CTNM

Charles Schwab’s Contineum Therapeutics CTNM Stock Holding History

Charles Schwab’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.51M Buy
214,082
+70,073
+49% +$919K ﹤0.01% 2614
2026
Q1 		$1.88M Buy
144,009
+33,948
+31% +$455K ﹤0.01% 2735
2025
Q4 		$1.26M Sell
110,061
-117
-0.1% -$1.33K ﹤0.01% 2853
2025
Q3 		$1.29M Buy
110,178
+84,139
+323% +$678K ﹤0.01% 2870
2025
Q2 		$103K Sell
26,039
-25,163
-49% -$109K ﹤0.01% 3415
2025
Q1 		$357K Sell
51,202
-4,128
-7% -$37.5K ﹤0.01% 3164
2024
Q4 		$811K Buy
55,330
+12,035
+28% +$191K ﹤0.01% 2977
2024
Q3 		$829K Sell
43,295
-8,477
-16% -$163K ﹤0.01% 2980
2024
Q2 		$912K Buy
+51,772
New +$834K ﹤0.01% 2972

Other funds holding CTNM

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Charles Schwab's CTNM Position: Q2 2026 in Review

Charles Schwab increased its Contineum Therapeutics (CTNM) stake by 49% in Q2 2026, buying an estimated $919K and bringing the position to 214,082 shares worth $3.51M. The position accounts for ﹤0.01% of the portfolio, ranked #2614.

Charles Schwab first reported a position in CTNM in Q2 2024 and has held it in 9 quarters since. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

  • Charles Schwab held 214,082 shares of Contineum Therapeutics worth $3.51M as of Q2 2026.
  • Charles Schwab bought 70,073 Contineum Therapeutics shares in Q2 2026, an estimated $919K.
  • Contineum Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2614 holding.
  • Charles Schwab first reported a position in Contineum Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.